10-Q: Butterfly Network Reports Increased Revenue and Reduced Operating Expenses in Q3 2024

Butterfly Network saw a significant increase in product revenue and a decrease in operating expenses in the third quarter of 2024, while still reporting a net loss.

Summary

• Butterfly Network reported a total revenue of $20.6 million for the third quarter of 2024, compared to $15.4 million in the same period of 2023.
• Product revenue increased by 54.7% to $13.5 million, driven by higher sales of the iQ3 probe and international expansion.
• Software and other services revenue grew by 5.3% to $7.0 million, primarily due to increased enterprise software revenue.
• The company's gross profit was $12.2 million, up from $9.4 million in the prior year.
• Operating expenses decreased to $29.5 million from $41.9 million, mainly due to reduced research and development and general and administrative costs.
• The net loss for the quarter was $16.9 million, an improvement from the $27.4 million loss in the third quarter of 2023.
• For the nine months ended September 30, 2024, total revenue was $59.7 million, compared to $49.4 million in the same period of 2023.
• The company's cash and cash equivalents were $93.8 million as of September 30, 2024.
• Butterfly Network expects its current cash reserves to fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and cost reduction, but the company is still operating at a loss and may need to raise capital. The sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in product revenue, driven by the launch of the iQ3 probe and international expansion.
• Operating expenses were substantially reduced due to cost-cutting measures, including reductions in force.
• The net loss improved compared to the same period last year, indicating progress towards profitability.
• The company's cash position is expected to be sufficient to fund operations for at least the next twelve months.
• International sales saw a large increase due to new distribution agreements.
• Enterprise software revenue increased as a percentage of total software revenue.

Negatives

• The company continues to operate at a net loss, despite improvements in revenue and cost management.
• Software and other services mix decreased by 9.0 percentage points, to 34.2% for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
• The company may need to raise capital before reaching profitability.
• The company has ongoing legal proceedings that could impact its financial results.

Risks

• The company's growth depends on its ability to attract and retain customers.
• The company's business could be harmed if it fails to manage its growth effectively.
• The company's projections are subject to risks, assumptions, estimates, and uncertainties.
• The company is subject to a variety of U.S. and foreign laws, which are subject to change and could adversely affect its business.
• The company faces competition from other companies marketing or developing ultrasound imaging devices.
• Economic downturns and political and market conditions beyond the company's control could adversely affect its business.
• The company has ongoing legal proceedings that could impact its financial results.
• The company may need to raise capital in the future, which could dilute existing shareholders.

Future Outlook

The company expects its current cash reserves to fund operations for at least the next twelve months, but may need to raise capital before reaching profitability. The company plans to continue investing in its business to grow revenue and will first seek non-dilutive capital before considering equity financing.

Management Comments

• Management believes that the company's cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.
• The company plans to continue to invest in its business in order to grow revenue.
• The company will first seek nondilutive capital in the form of licensing, grants, or debt and then potentially in the form of equity securities.

Industry Context

The company operates in the competitive medical imaging market, facing competition from established players with greater resources. The company's focus on portable, affordable ultrasound technology positions it to potentially disrupt the market by making medical imaging more accessible. The company's growth in international markets and enterprise software sales indicates a positive trend in market adoption.

Comparison to Industry Standards

• Butterfly Network's revenue growth of 33.3% in Q3 2024 is strong compared to some established medical device companies, but it is important to note that the company is still in a growth phase and not yet profitable.
• Companies like Philips and GE Healthcare, which are major players in the medical imaging market, have much larger revenue bases but may not be growing as quickly in the portable ultrasound segment.
• Butterfly's focus on software and services is similar to trends in the broader healthcare technology industry, where recurring revenue models are increasingly valued.
• The company's reduction in operating expenses is a positive sign, as many growth-stage companies struggle with cost control.
• Compared to other medical device companies, Butterfly Network's cash burn rate is still high, but the company has taken steps to reduce it.

Management Changes

Legal Proceedings

• The company is involved in litigation and legal matters from time to time, which have arisen in the normal course of business.
• A putative class action lawsuit, styled Rose v. Butterfly Network, Inc., et al. was filed in the United States District Court for the District of New Jersey.
• A stockholder derivative action, styled Koenig v. Todd M. Fruchterman, et al. was filed in the United States District Court for the District of Delaware.
• A stockholder derivative action, styled Bhavsar v. Todd M. Fruchterman, et al. was filed in the United States District Court for the District of Delaware.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and cost reductions, but concerned about the ongoing losses and potential need for capital raises.
• Employees may be affected by the company's cost-cutting measures, including reductions in force.
• Customers may benefit from the company's innovative and affordable ultrasound technology.
• Suppliers may be impacted by the company's inventory purchase commitments.

Next Steps

• The company plans to continue to invest in its business in order to grow revenue.
• The company will first seek nondilutive capital in the form of licensing, grants, or debt and then potentially in the form of equity securities.

Key Dates

Keywords

ultrasound, medical devices, digital health, revenue, operating expenses, net loss, software, SaaS, iQ3, financial results, healthcare, medical imaging